Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Work In Process (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Work In Process for 14 consecutive years, with $13.7 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 75.93% to $13.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Dec 2025, up 75.93% year-over-year, with the annual reading at $13.7 million for FY2025, 75.93% up from the prior year.
  • Work In Process hit $13.7 million in Q4 2025 for Corcept Therapeutics, down from $14.2 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $14.9 million in Q1 2021 to a low of $6.7 million in Q2 2023.
  • Historically, Work In Process has averaged $10.4 million across 5 years, with a median of $10.0 million in 2022.
  • Biggest five-year swings in Work In Process: plummeted 41.28% in 2023 and later soared 82.86% in 2025.
  • Year by year, Work In Process stood at $11.4 million in 2021, then crashed by 31.64% to $7.8 million in 2022, then rose by 5.19% to $8.2 million in 2023, then dropped by 5.39% to $7.8 million in 2024, then surged by 75.93% to $13.7 million in 2025.
  • Business Quant data shows Work In Process for CORT at $13.7 million in Q4 2025, $14.2 million in Q3 2025, and $11.8 million in Q2 2025.